A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis

作者：Taguchi Atsumi; Maruyama Hiroki; Nameta Masaaki; Yamamoto Tadashi; Matsuda Junichiro; Kulkarni Ashok B; Yoshioka Hidekatsu; Ishii Satoshi^*

来源：Biochemical Journal, 2013, 456: 373-383.

DOI：10.1042/BJ20130825

• enzyme replacement therapy
• Fabry disease
• globotriaosylceramide synthesis
• symptomatic mouse model

Fabry disease is a lysosomal storage disorder in which neutral glycosphingolipids, predominantly Gb3 (globotriaosylceramide), accumulate due to deficient alpha-Gal A (alpha-galactosidase A) activity. The GLAko (alpha-Gal A-knockout) mouse has been used as a model for Fabry disease, but it does not have any symptomatic abnormalities. In the present study, we generated a symptomatic mouse model (G3Stg/GLAko) by cross-breeding GLAko mice with transgenic mice expressing human Gb3 synthase. G3Stg/GLAko mice had high Gb3 levels in major organs, and their serum Gb3 level at 5-25 weeks of age was 6-10-fold higher than that in GLAko mice of the same age. G3Stg/GLAko mice showed progressive renal impairment, with albuminuria at 3 weeks of age, decreased urine osmolality at 5 weeks, polyuria at 10 weeks and increased blood urea nitrogen at 15 weeks. The urine volume and urinary albumin concentration were significantly reduced in the G3Stg/GLAko mice when human recombinant alpha-Gal A was administered intravenously. These data suggest that Gb3 accumulation is a primary pathogenic factor in the symptomatic phenotype of G3Stg/GLAko mice, and that this mouse line is suitable for studying the pathogenesis of Fabry disease and for preclinical studies of candidate therapies.

• 出版日期2013-12-15